With extensive experience in neurology research and clinical care, Advarra’s Central Neurology Review (CNR) provides the robust human subject protections review that research institutions prefer.
Planned emergency research (subject to the 21 CFR 50.24 regulations) is challenging for IRBs to review under any circumstance. Now, in the era of single IRB (sIRB), add in the…
IRBs are in a unique position to impact risk management in clinical research. Their role is designed to protect research participants, but this can also equate to elevating best practices…
Advarra offers the most comprehensive approach to Phase I research with experience overseeing thousands of Phase I studies in the US and Canada.
In this webinar, Michele Russell-Einhorn, JD, Advarra's CCO and IO, and Judith Carrithers, JD, Advarra's Director of Regulatory Affairs, discuss FAQs and common issues in implementing the revised Common Rule.
Judith Carrithers, JD, Director of Regulatory Services at Advarra, and Michele Russell-Einhorn, JD, Chief Compliance Officer and Institutional Official at Advarra, discuss a checklist of action items to consider and…
Luke Gelinas, PhD, IRB Chair at Advarra, discusses some of the oversight challenges presented by PCOR and shares policy recommendations for managing such challenges.
Advarra’s Canadian review service combines local, expert oversight with streamlined processes and the most extensive site reach in Canada to aid you in the conduct of efficient, responsible research.
Advarra serves as your external support and compliance partner for everything from single investigational sites to multisite research consortia and therapeutic networks.
Advarra provides flexible solutions that help accelerate the initial IRB review process and make it more efficient.